CN111182907B - 用于治疗膀胱癌的abx196 - Google Patents

用于治疗膀胱癌的abx196 Download PDF

Info

Publication number
CN111182907B
CN111182907B CN201880064390.5A CN201880064390A CN111182907B CN 111182907 B CN111182907 B CN 111182907B CN 201880064390 A CN201880064390 A CN 201880064390A CN 111182907 B CN111182907 B CN 111182907B
Authority
CN
China
Prior art keywords
bladder
treatment
bladder cancer
abx196
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880064390.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN111182907A (zh
Inventor
桑德琳·克拉伯
迪迪埃·席勒
哈特穆特·埃里希
菲利普·波莱蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wittycell
Original Assignee
Wittycell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wittycell filed Critical Wittycell
Publication of CN111182907A publication Critical patent/CN111182907A/zh
Application granted granted Critical
Publication of CN111182907B publication Critical patent/CN111182907B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880064390.5A 2017-09-13 2018-09-13 用于治疗膀胱癌的abx196 Active CN111182907B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306182.1 2017-09-13
EP17306182 2017-09-13
PCT/EP2018/074778 WO2019053142A1 (en) 2017-09-13 2018-09-13 ABX196 FOR USE IN THE TREATMENT OF BLADDER CANCER

Publications (2)

Publication Number Publication Date
CN111182907A CN111182907A (zh) 2020-05-19
CN111182907B true CN111182907B (zh) 2023-01-06

Family

ID=60001797

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880064390.5A Active CN111182907B (zh) 2017-09-13 2018-09-13 用于治疗膀胱癌的abx196

Country Status (18)

Country Link
US (1) US11266667B2 (enExample)
EP (1) EP3681512B1 (enExample)
JP (1) JP7214718B2 (enExample)
KR (1) KR102706165B1 (enExample)
CN (1) CN111182907B (enExample)
AU (1) AU2018332046B2 (enExample)
BR (1) BR112020004778A2 (enExample)
CA (1) CA3075443A1 (enExample)
CU (1) CU20200020A7 (enExample)
DK (1) DK3681512T3 (enExample)
ES (1) ES2893549T3 (enExample)
HR (1) HRP20211351T1 (enExample)
IL (1) IL273054B2 (enExample)
MX (1) MX394216B (enExample)
PL (1) PL3681512T3 (enExample)
PT (1) PT3681512T (enExample)
WO (1) WO2019053142A1 (enExample)
ZA (1) ZA202001435B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101917985A (zh) * 2007-12-05 2010-12-15 维迪瑟尔公司 糖基神经酰胺增强对抗原的免疫反应的用途
CN102215864A (zh) * 2008-10-08 2011-10-12 威蒂赛尔公司 用于抗流感的疫苗组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2654382T3 (es) 2011-01-05 2018-02-13 National Taiwan University Método para la preparación de glucoesfingolípidos
CN110831629B (zh) * 2016-09-14 2022-08-23 Abivax公司 用于治疗癌症的包括abx196的组合

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101917985A (zh) * 2007-12-05 2010-12-15 维迪瑟尔公司 糖基神经酰胺增强对抗原的免疫反应的用途
CN102215864A (zh) * 2008-10-08 2011-10-12 威蒂赛尔公司 用于抗流感的疫苗组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth;Tomoe Higuchi;《Cancer Immunol Immunother》;20090112;第58卷(第8期);1245-1255 *
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination;Josianne Nitcheu Tefit等;《Vaccine》;20140913;第32卷(第46期);6138-6145 *

Also Published As

Publication number Publication date
AU2018332046A1 (en) 2020-03-19
IL273054A (en) 2020-04-30
EP3681512A1 (en) 2020-07-22
IL273054B1 (en) 2023-01-01
CA3075443A1 (en) 2019-03-21
PT3681512T (pt) 2021-10-06
WO2019053142A1 (en) 2019-03-21
MX394216B (es) 2025-03-24
HRP20211351T1 (hr) 2021-11-26
CN111182907A (zh) 2020-05-19
KR20200102412A (ko) 2020-08-31
KR102706165B1 (ko) 2024-09-13
DK3681512T3 (da) 2021-09-06
CU20200020A7 (es) 2020-11-30
MX2020002812A (es) 2020-07-21
JP7214718B2 (ja) 2023-01-30
BR112020004778A2 (pt) 2020-10-13
AU2018332046B2 (en) 2024-06-13
JP2020533368A (ja) 2020-11-19
RU2020109889A3 (enExample) 2022-01-28
PL3681512T3 (pl) 2022-01-17
US11266667B2 (en) 2022-03-08
RU2020109889A (ru) 2021-09-06
US20200230163A1 (en) 2020-07-23
ES2893549T3 (es) 2022-02-09
IL273054B2 (en) 2023-05-01
ZA202001435B (en) 2022-07-27
EP3681512B1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
CN109153723B (zh) 抗pd-1抗体与放射的组合治疗癌症
JP5437306B2 (ja) 抗体療法
CN105452294B (zh) 癌的治疗和/或预防用药物组合物
JP7769032B2 (ja) 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
CN108602889A (zh) 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
KR20210054528A (ko) Cd3/c20 이중특이적 항체에 대한 사이토카인 방출 증후군을 경감시키는 투약 전략
CN100548374C (zh) 用ⅲ类抗cea单克隆抗体和治疗剂进行联合治疗
CN108602891A (zh) 治疗尿道恶性肿瘤的多特异性抗体
US11826372B2 (en) Combinations including ABX196 for the treatment of cancer
TW202133886A (zh) 用於增強免疫及腫瘤治療之方法
CN111182907B (zh) 用于治疗膀胱癌的abx196
CN113038939A (zh) 损害内施用pd-1抑制剂用于治疗皮肤癌
RU2778812C2 (ru) Abx196 для применения при лечении рака мочевого пузыря
CN121127264A (zh) 用于在治疗黑素瘤中增强疗效的pd-1抑制剂和lag-3抑制剂组合
WO2025256641A1 (zh) 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤
TW202537643A (zh) 抗體-藥物結合物之用途
HK40005822A (en) Antibody-sn-38 immunoconjugates with a cl2a linker
HK40011701B (en) Combinations including abx196 for the treatment of cancer
HK40011701A (en) Combinations including abx196 for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant